New York, February 25, 2026, 06:14 EST — Premarket
- Iovance rose roughly 4% in early premarket trading, following Tuesday’s 30.8% surge.
- The company pulled in around $87 million in product revenue during the fourth quarter, with gross margin landing close to 50%.
- Citizens lifted its rating on the stock to Market Outperform, setting a price target of $5.
Iovance Biotherapeutics jumped roughly 4% in premarket action Wednesday, following up on Tuesday’s 30.8% rally. Traders zeroed in on the most recent earnings release and a new analyst upgrade.
This matters for Iovance, which is still out to prove itself—selling a complicated, single-use cancer cell therapy that hinges on hospital bandwidth, referral flows, and the pace of manufacturing rather than drug prices alone.
Cell therapies targeting solid tumors may appear simple during presentations, but the reality is often more complicated. Iovance is relying on its expanding network of authorized treatment centers to bring Amtagvi—a tumor-infiltrating lymphocyte (TIL) therapy built from the patient’s own immune cells—to patients.
Iovance logged roughly $87 million in product revenue for the fourth quarter, according to a filing with U.S. regulators, while gross margin from cost of sales landed at about 50%. The company reported a net loss of $71.9 million, or 18 cents a share. Cash and equivalents totaled around $303 million at the end of 2025, which management expects will cover operations through the third quarter of 2027.
The company highlighted some initial numbers from a lifileucel pilot in aggressive soft tissue sarcomas: a 50% objective response rate among the first six patients who could be evaluated—that’s tumor shrinkage by a defined margin. Lauren Baker Banks, sarcoma medical oncologist at Memorial Sloan Kettering Cancer Center, described the responses as “compelling and unprecedented.” For Iovance, executive Brian Gastman argued the data point to the therapy’s potential as “a new, highly efficacious, and durable” treatment. GlobeNewswire
Citizens lifted its rating on Iovance to “Market Outperform” from “Market Perform” and placed a $5 price target, citing indications that initial launch hurdles might be smoothing out as the company’s manufacturing operations and treatment-center network find steadier footing. Investing
Iovance has refreshed the corporate presentation it shares at healthcare conferences and in talks with analysts and investors, according to a company filing.
Still, familiar pitfalls remain. Early response rates in small trials sometimes drop off once more patients are added, and regulators might insist on bigger studies with longer follow-up before considering a broader label. Iovance faces another challenge: keeping its manufacturing pace in sync with hospital capacity—if either lags, that revenue can lose steam in a hurry.
Guidance is the next question. Interim CEO Frederick Vogt, speaking on Tuesday’s call, said 2026 revenue guidance would arrive “in the very near future.” Traders eye that as the next cue after this week’s surge. Fool
